Evidence analysis of the results of the study of the use of the drug Amizon® Max in treatment of COVID-19 compared with placebo

December 6, 2021
1071
Resume

Evidence analysis of the study «Multicenter, double-blind, randomized, placebo-controlled study of the effectiveness and safety of Amizon® Max, 0.5 g capsules, manufactured by JSC «Farmak», in combination with basic therapy, in patients with COVID-19, which is caused by SARS-CoV-2 virus, moderate severity» indicates that this study is planned and conducted in accordance with the principles of evidence-based medicine and has the highest level of evidence, as according to the rating system for assessing the evidence of clinical trials, it can be classified as class I (A), namely a double-blind, randomized, placebo-controlled study. The parameters of the study indicate that it has a high degree of representativeness and its results can be generalized to the target population. The study is in line with Good Clinical Practice principles, as evidenced by an international audit. 592 patients from different regions of Ukraine (14 clinical centers) took part in the study. As a result, the predominant efficacy of Amizon® Max in the treatment of COVID-19 compared with placebo was proven, namely therapy with Amizon® Max significantly (p=0.00945; unilateral) accelerates the onset of improvement in patients with COVID-19 by 2 points per modified the World Health Organization’s scale compared to placebo-treated patients. In addition, the use of Amizon® Max accelerates the recovery process of patients, especially in early use (immediately at the first symptoms), prevents deterioration of the patient’s condition and, consequently, lethal outcome, accelerates the reduction of cough, has more effective effect in patients aged >50 years.

References

  • 1. Clinical Trials of Drugs (2006) (Eds.) Maltsev V.I., Efimtseva T.K., Belousov Yu.B., Kovalenko V.N. 2nd ed., reworked. Morion, Kiev, 456 p.
  • 2. European Commission: EudraLex — Volume 4 EU Guidelines to Good Manufacturing Practice (GMP), Medicinal Products for Human and Veterinary Use: Annex 13 Investigational Medicinal Products. Revision 1. Brussels, 03 Febr. 2010 (ENTR/F/2/AM/an D (2010) 3374.
  • 3. Remdesivir for the Treatment of Covid-19 — Final Report. New Engl. J. Med. Downloaded from nejm.org on Oct. 8, 2020.
  • 4. World Health Organization (2020) WHO R&D Blueprint: novel Coronavirus, COVID-19 Therapeutic Trial Synopsis, Febr. 18, 2020.
  • 5. Mehta C.R., Pocock S.J. (2000) Adaptive Increase in Sample Size when Interim Results are Promising: A Practical Guide with Examples. Statist. Med.: 1–6.
  • 6. Broberg P. (2013) Sample size re-assessment leading to a raised sample size does not inflate type I error rate under mild conditions: BMC Med. Res. Methodol., 13: 94.
  • 7. Bauer P., Köhne K. (1994) Evaluation of experiments with adaptive interim analyses. Biometrics, 50: 1029–1041.
  • 8. Fletcher R., Fletcher S., Wagner E. (1998) Clinical Epidemiology. Basics of Evidence-Based Medicine. Transl. from English, Moscow, MediaSphere, 320 p.
  • 9. European Medicines Agency (1998) ICH Topic E9, Note for Guidance on Statistical Principles for Clinical Trials (CPMP/ICH/363/96). Final approval by CPMP: March 1998.